Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMA8KQR)

Drug Name

GB0139 Drug Info

Synonyms

TD139; TD-139; 1450824-22-2; olitigaltin; TD 139; GB0139; GB-0139; Olitigaltin [USAN]; 60Y0GUO72B; 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-Beta-D-Galactopyranosyl 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-1-Thio-Beta-D-Galactopyranoside; (2R,2'R,3R,3'R,4S,4'S,5R,5'R,6S,6'S)-6,6'-Thiobis(4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol); (2S,3R,4S,5R,6R)-4-[4-(3-Fluorophenyl)triazol-1-yl]-2-[(2S,3R,4S,5R,6R)-4-[4-(3-fluorophenyl)triazol-1-yl]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol; UNII-60Y0GUO72B; TD2; OLITIGALTIN [INN]; Gal-3 Inhibitor GB0139; Galectin-3 Inhibitor GB0139; CHEMBL4297442; SCHEMBL15657269; TD 139 [WHO-DD]; GTPL12148; EX-A1688; BDBM50581762; WHO 12032; AKOS027325618; CS-6265; DB12895; GB 0139; AC-35516; beta-D-Galactopyranoside, 3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-beta-D-galactopyranosyl 3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-1-thio-; BS-15429; BT173009; HY-19940; C72753; A857944; Q27263259; bis-(3-deoxy-3-(3-fluorophenyl-1h-1,2,3-triazol-1-yl)-beta-d-galactopyranosyl)-sulfane; .BETA.-D-GALACTOPYRANOSIDE, 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1-THIO-; 3,3'-DIDEOXY-3,3'-BIS-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1,1'-SULFANEDIYL-DI-.BETA.- D-GALACTOPYRANOSIDE; BIS(3-DEOXY-3-(3-FLUOROPHENYL-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL)SULFANE

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]

Cross-matching ID

PubChem CID: 73774610
TTD Drug ID: DMA8KQR

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Galectin-3 (LGALS3)	TTFPQV7	LEG3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Idiopathic pulmonary fibrosis

ICD Disease Classification

CB03.4

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Galectin-3 (LGALS3)	DTT	LGALS3	4.24E-01	-0.05	-0.08

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03832946) GALACTIC-1 -A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor Administered Via a Dry Powder Inhaler Over 52 Weeks. U.S.National Institutes of Health.
2	An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE). Am J Respir Crit Care Med. 2023 Jan 15;207(2):138-149.